Dipexium Pharmaceut (DPRX) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Dipexium Pharmaceuticals Reports First Quarter 2015 Financial Results
May 14, 2015 7:30 AM EDTNEW YORK, May 14, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today reported financial results for the quarter ended March 31, 2015.Â
"We successfully advanced our drug development program in the first quarter of 2015 and hope to continue that progress moving forward," stated David P. Luci, President & Chief Executive Officer of Dipexium. "We continue to manage and maintain our cash reserves consistent with our prior guidance."
Financial Results for the First... More
